Ono Pharmaceutical (OTCMKTS:OPHLF) Co., Ltd. is a Japan-based biopharmaceutical company engaged in the research, development, manufacturing and marketing of prescription pharmaceuticals and over-the-counter products. The company maintains a broad portfolio that spans oncology, immunology, neurology, cardiovascular and metabolic diseases, as well as anti-infectives and pain management therapies. Its pharmaceutical pipeline combines small-molecule compounds and biologics, reflecting a balanced approach to both traditional drug discovery and cutting-edge immuno-oncology research.
Ono Pharmaceutical is best known globally for its collaboration with Bristol-Myers Squibb on nivolumab (Opdivo), a monoclonal antibody indicated for multiple cancer types, which has helped establish the firm’s reputation in immuno-oncology. Beyond this flagship product, the company markets non-prescription products for allergy relief and dermatological conditions in Japan, while also commercializing veterinary drugs that address livestock health and companion animal welfare. Its research centers focus on next-generation targeted therapies, antibody-drug conjugates and combination regimens designed to improve patient outcomes.
Headquartered in Chuo-ku, Osaka, the company serves markets across Asia, Europe and North America through a network of subsidiaries and strategic partnerships. In Japan, Ono Pharmaceutical operates manufacturing facilities and research laboratories, while its global footprint is supported by distribution agreements and co-development alliances. This international reach allows the company to leverage regional regulatory expertise and local market knowledge, facilitating the launch of new therapies in diverse healthcare systems.
Tracing its origins to an Osaka drugstore established in the early 18th century, Ono Pharmaceutical has evolved into a modern life sciences enterprise. The company is led by a seasoned management team under the leadership of its Representative Director and President, who emphasize innovation, patient centricity and sustainable growth. With a corporate philosophy that balances scientific excellence and social responsibility, Ono Pharmaceutical continues to pursue novel treatments that address unmet medical needs worldwide.
